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ABSTRACT 
Dengue virus is a mosquito-borne pathogen that causes dengue diseases. All four serotypes of dengue virus are 
infectious for humans. Therefore, an efficacious dengue vaccine should be tetravalent to provide protection 
against all types of virus. The goal of this study was to design a new tetravalent recombinant protein from enve-
lope protein of dengue viruses to induce virus-neutralizing antibodies against all four serotypes in mice. A chi-
meric protein was designed from domain III of envelope protein of all serotypes of dengue virus. Four domain 
III fragments were linked together by alpha helix making linkers. The final sequence of the designed protein was 
analyzed in silico and the coding gene sequence was deduced by reverse translation. After cloning and expres-
sion of the recombinant protein (ED3-tetravalent protein), identity of the purified protein was confirmed using a 
pan-dengue specific monoclonal antibody in Western blotting. Then, the immunogenicity of the purified protein 
was studied in mice using antibody titration. The efficacy of induced antibodies in neutralization of the virus was 
studies by FRNT method. Furthermore, the induction of cellular immunity was studied by measurement of cyto-
kines using ELISA method and measurement of lymphocyte proliferation using MTT assay. The ED3-tetravalent 
protein was able to enhance neutralizing immunogenic response against all four dengue serotypes; in similar way 
to that of tetravalent formulation of four individual domain III-based polypeptides. It is suggested that the ED3-
tetravalent fusion protein can induce broadly neutralizing antibody responses against all four serotypes of dengue 
virus in mice.  
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INTRODUCTION 
Dengue virus is a mosquito-borne patho-
gen that causes dengue fever, dengue shock 
syndrome (DSS), and dengue hemorrhagic 
fever (DHF). Recently the reports for dengue 
infections have been increased, especially 
among people who live in warm and humid 
areas. These viruses are transmitted to hu-
mans through the bites of "Stegomyia”; es-
pecially Aedes albopictus and Aedes aegypti 
(Gubler, 1998, 2002; Whitehorn, 2012). All 
dengue serotypes (serotypes 1-4) can infect 
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human and because there is no efficient cross 
protection between the various serotypes, a 
perfect dengue vaccine should be a tetrava-
lent vaccine (Guzman et al., 2010). Accord-
ing to the report from “WHO” website, 
Sanofi Pasteur developed a live-attenuated 
multivalent vaccine, Dengvaxia (CYD-TDV) 
which was recently licensed in Mexico and 
several countries. However, considering 
some safety issues, designing a novel tetra-
valent subunit vaccine with efficient im-
mune-protective properties is remained as an 
attractive subject.  
Several publications have reported the 
creation of effective vaccine candidates on 
the basis of conventional live attenuated vi-
ruses, inactivated viruses, from infectious 
clone derived attenuated viruses, and genetic 
vaccines (Swaminathan and Khanna, 2010; 
Murrell et al., 2011; Schmitz et al., 2011). 
Recently, considerable research has also 
been directed towards the production of re-
combinant subunit vaccines (Whitehead and 
Subbarao, 2017). Since subunit vaccines use 
merely a specific portion of pathogen, vac-
cines produced this way can be considered 
easier, cheaper, safer and more stable than 
the live attenuated dengue vaccines 
(Clements et al., 2010). Therefore, most of 
recent investigations are focused on envelope 
protein of dengue virus (E protein). The E 
protein mediates virus entry into host cells 
via receptor–binding (Henchal and Putnak, 
1990). The dengue E protein consists of 
three domains (I, II, and III) (Modis et al., 
2004) of which the domain III (ED3) appears 
to play critical roles in the next step of virus 
entry into the host cell. It is also very potent 
in induction of immune-protective responses 
against the virus. It has been reported that 
the anti-ED3 specific monoclonal antibodies 
can block virus entry and infectivity. In con-
trast, domains I or II-specific antibodies have 
represented lower avidity and cross neutrali-
zation properties (Chávez et al., 2010; Modis 
et al., 2005). Several investigations have 
shown that the recombinant ED3 proteins 
can inhibit dengue infectivity, and induce 
dengue-neutralizing immunoglobulin in 
mice. Taken together, the critical region of 
the E protein for vaccine design and devel-
opment have been identified on ED3 
(Hermida et al., 2006; Mota et al., 2005; 
Babu et al., 2008; Leng et al., 2009; Khanam 
et al., 2006; Zhang et al., 2015; Chiang et al., 
2013; Suzarte et al., 2014; Fahimi et al., 
2013, 2014, 2018; Kulkarni et al., 2017; 
Gottschamel et al., 2016). In this study, a 
new tetravalent protein was designed and 
expressed based on consensus ED3 of all 
dengue serotypes. The designed chimeric 
protein (ED3-tetravalent protein) was ex-
pressed in bacterial host and after purifica-
tion and formulation with proper adjuvant 
the analysis of the immunogenic responses 
was carried out on mice. It was shown that 
this fusion protein can induce antibodies in 
mice which were able to cross-neutralize all 
dengue serotypes in vitro. This approach can 
be very effective for simultaneously induc-
tion of protective antibodies for all dengue 
virus serotypes by a recombinant protein, 
and potentially offers advantages over the 
tetravalent mixture of four domain III frag-
ments. 
 
MATERIAL AND METHODS 
Cells and viruses 
Four serotypes of the dengue virus, 
(DENV 1 strain 16007, DENV2 strain Th-
NH-81/93, DENV3 strain BR/D3LIMHO/ 
2006, DENV4 strain PH/BID-V3361/1956), 
were used for this study. Virus propagation 
and titration was performed in Vero B4 cells. 
All obtained from Bernhard Nocht Institute 
for Tropical Medicine (BNITM, Germany). 
Cells were maintained in Dulbecco's Modi-
fied Eagle's Medium (DMEM) with 4.5 g/l 
glucose [were obtained from PAA Laborato-
ries, Colbe, Germany] supplemented with 
10 % (v/v) heat inactivated fetal calf serum 
(FCS) [PAA], 2 mM glutamate [PAA], 
50 U/ml penicillin and 50 µg/ml streptomy-
cin [Gibco] in a 5 % CO2 humidified incuba-
tor, at 37 °C.  
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Designing and construction of ED3  
sequences 
Four consensus ED3 sequences were 
provided corresponding to the four dengue 
serotypes and designed a tetravalent antigen 
by fusing these fragments together, as re-
ported previously (Fahimi et al., 2016). 
Briefly, the amino acid sequences of ED3 
from all four serotypes were obtained from 
GenBank and multiple sequence alignment 
by using ClustalW software was performed 
in order to identify an amino acid sequence 
common in different isolates of the four 
serotypes. Four consensus ED3 peptide se-
quences were used for designing a tetrava-
lent fusion protein (ED3F: GenBank acces-
sion no. JN985899). In order to achieve high 
expression level, the codons were optimized 
for Escherichia coli by using Optimizer 
(http://genomes.urv.es/OPTIMIZER/). For 
cloning purposes, restriction sites of Nde I 
and Xho I enzymes were introduced at the 5' 
and the 3' sites, respectively. The target gene 
was synthesized by Eurofins MWG Operon 
(Germany), and sub-cloned into pET21a(+) 
expression vector (Novagen). As a result, the 
carboxyl terminus of the recombinant protein 
contains a hexa-histidine tag (His6-Tag).  
 
Expression and purification of recombinant 
protein 
The constructed expression vector 
(pETD3F) was transformed into E. coli 
DH5α for plasmid amplification and into E. 
coli Origami(DE3) for protein expression. A 
single colony of transformed E. coli was 
grown overnight at 37 ºC in 5 ml LB medi-
um containing 50 μg/ml ampicillin, 12.5 
μg/ml tetracycline, and 15 μg/ml kanamycin 
(Sigma-Aldrich, St. Louis, MO, USA). Then 
the cultures were diluted 1:100 in LB medi-
um containing antibiotics as described before 
and further incubated at 37 ºC. The cultures 
were induced in the logarithmic phase (at 
OD600 of 0.6) by addition of isopropyl β-D-
1-thiogalactopyranoside (IPTG) to a final 
concentration of 1 mM. After 4 hours, the 
expression of the recombinant ED3F was an-
alyzed by SDS-PAGE (Laemmli, 1970). The 
recombinant protein prepared from soluble 
fraction of Origami(DE3) cell lysate were 
purified using Nickel–nitrilotriacetic acid 
(Ni–NTA) (Qiagen, Germany) resin under 
native condition, according to manufacturer's 
instruction. The protein concentrations were 
analyzed by Bradford protein assay 
(Bradford, 1976). Furthermore, the four con-
sensus ED3 proteins were expressed and as-
sessed for immunogenicity, similar to the 
previous report (Fahimi et al., 2014). The 
origami (DE3) strain of E. coli was used as 
an expression host.  
 
Immunoassay procedures 
For Western blot analysis the purified 
proteins were applied on a 10 % SDS-PAGE 
and transferred onto nitrocellulose mem-
brane by using a semidry (Bio-Rad, Califor-
nia, United States) system (Tris 12.5 mM, 
Glycine 96 mM, SDS 0.03 %, and methanol 
10 % with pH 8.3). The membrane was in-
cubated in the blocking buffer of 5 % 
skimmed milk at 4 ºC overnight. It was then 
incubated in a 1:1000 diluted primary anti-
body, anti-HisTag (Abcam, UK) or pan-
dengue specific monoclonal antibody (cat 
no. MAB4043, Abnova), with gentle shaking 
for 2 hours at room temperature (RT). The 
membrane was washed three times with 
PBST (PBS containing 0.1 % Tween 20) and 
then incubated in secondary antibody, a 
1:2000 dilution of HRP-conjugated rabbit 
anti mouse IgG antibody (Abcam, UK), with 
gentle shaking for 1 h at RT. After a 15 min 
washing with PBST, the detection was per-
formed using diaminobenzidine (DAB) as a 
chromogenic substrate. Dot blotting analysis 
was performed using a very similar method 
like Western blotting. Briefly, recombinant 
proteins were dotted on nitrocellulose mem-
brane strips and were reacted with diluted se-
rum samples from the immunized animals. 
Blocking, antibody incubation, and detection 
methods were identical with Western blot-
ting, except the serum dilutions were 1:10 
and the chromogenic substrate was 4-
Chloro-1-naphthol (Sigma-Aldrich, St. Lou-
is, MO, USA).  
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Animal immunizations 
Male BALB/c mice were obtained from 
Pasteur Institute (Tehran, Iran). Groups of 
six mice (6-8 weeks of age) were immunized 
subcutaneously with the recombinant pro-
teins formulated with Freund's complete ad-
juvant (FCA, Sigma-Aldrich, St. Louis, MO, 
USA) for priming (day 0), and with Freund's 
incomplete adjuvant (FIA, Sigma-Aldrich, 
St. Louis, MO, USA) for two booster im-
munizations (days 14 and 28). A group of 
mice were injected with PBS in combination 
with adjuvant, as negative control group 
(Table 1). Since immunogenicity properties 
of FCA/ FIA are more potent than popular 
adjuvant-alum, FCA/FIA was used for this 
experiment. The mice were sacrificed and 
blood collected, 14 days after the last im-
munization, and pooled sera were stored at -
80 ºC until use. All procedures were per-
formed according to the guidelines of the 
Medical Ethics Committee of Tarbiat Mo-
dares University, Tehran, Iran (D52/6854). 
 
Table 1: Antigens used for immunization of the 
mice 
Groups* Antigens Amount  
per dose 
G1 ED3-1 20 µg 
G2 ED3-2 20 µg 
G3 ED3-3 20 µg 
G4 ED3-4 20 µg 
G5 #)4-1(ED3 80 µg 
G6 ED3-F 80 µg 
G7 FBS - 
* Each group consists of six animals. 
# Mixture of ED3 antigens representing all DENV 
serotypes 
 
 
Measurement of humoral antibody 
response in immunized mice 
The levels of anti-ED3(1-4)/anti-ED3F 
IgG in the serum samples were determined 
by using an indirect enzyme-linked immuno-
sorbent assay (ELISA). Polystyrene 96-well 
plates (Nunc-Immuno Plate MaxiSorp sur-
face, Nunc, Denmark) were coated with puri-
fied proteins (0.1 µg/well) then were incu-
bated overnight at 4 °C. The washing step 
was performed three times with PBST (PBS-
buffer containing 0.05 % Tween 20) and the 
blocking step was carried out by using 5 % 
skimmed milk in PBS for 1 h at 37 ºC. 
Mouse serum samples were serially diluted 
(100 μl/well) in blocking buffer (1:100 to 
1:12800, and incubated for 2 h at 37 ºC. Af-
ter washing, bounded IgG was detected with 
horseradish peroxidase-conjugated rabbit an-
ti-mouse IgG Fc (Abcam, UK), diluted 
1:4000 in blocking buffer. Finally, 100 μl of 
3,3',5,5'-tetramethylbenzidine (TMB) as 
chromogenic substrate were added and the 
plates were incubated at RT for 15 min. The 
reaction was stopped by adding 100 μl of 2N 
sulfuric acid and the absorbance at 450 nm 
was performed by using ELISA reader (Bio-
Rad). 
 
Focus reduction neutralization tests 
(FRNT) 
Anti-dengue neutralizing antibodies were 
detected by using a focus reduction neutrali-
zation test (FRNT), as reported previously 
(Leng et al., 2009). Briefly, the pooled serum 
samples from each group were heat inacti-
vated for 30 min at 56 °C. Vero B4 cells 
were seeded into 96-well cell culture plates 
[Sarstedt] to reach a confluence of 90 % after 
24 h. The pooled sera were used to prepare 
twofold serial dilutions in DMEM medium 
starting at 1:10. Then, the diluted sera were 
mixed 1:1 with virus suspensions in 96 well 
cell culture plates and incubated for 1 h at 
37°C. Virus suspensions were contained 
~100 focus forming unit (FFU) of each sero-
type per well. In order to viral adsorption, 
the Vero cell cultures were inoculated with 
the prepared serum-virus mixes and incubat-
ed for 1 h. Remaining infectivity was then 
assayed on cell monolayers overlaid with 
DMEM containing 0.8 % (w/v) methylcellu-
lose with 20 mM Tris. After 2 days of incu-
bation at 37 °C with 5 % CO2, the overlay 
medium was removed from the wells, and 
the Vero cells were washed with PBS. The 
cells were fixed for 20 min in 3.7 % formal-
dehyde/PBS and were washed with PBS. 
Then the cells were permeabilized with 
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0.5 % triton X-100/PBS for 20 min and 
blocked with 10 % fetal calf serum/PBS for 
30 min. Infected cells were detected by 
DENV serotype-specific monoclonal anti-
bodies. After washing with PBS, antibody-
labeled cells were detected using a HRP-
conjugated secondary antibody [Biorad, Cal-
ifornia, USA]. The labeling was visualized 
using precipitating tetramethylbenzidine 
(TMB) substrate [Mikrogen Diagnostik, 
Neuried, Germany]. The highest serum dilu-
tion that reduced the number of focuses by at 
least 50 % (FRNT50) in comparing with the 
control was calculated as the end-point neu-
tralizing antibody titer. The control samples 
were containing the virus and mock-
immunized sera as well as samples with vi-
rus alone. 
To investigate reactivity of the serum 
samples with dengue infected cells a very 
similar method with FRNT was used. Brief-
ly, Vero B4 cells were seeded into 96-well 
cell culture plates to reach a confluence of 
90 % after 24 h. The infection step was per-
formed by adding of 100 tissue culture infec-
tive dose 50 (TCID50) of each serotype of 
dengue virus. Cells were then overlayed (at 
37 °C with 5 % CO2 for 48 h). Afterward, 
the overlay medium was removed, and the 
cells were washed with PBS. Cells were then 
permeabilized and blocked according to the 
mentioned procedures. Infected cells were 
detected by 1:10 dilution of different serum 
samples from the immunized mice for 2 h. 
After washing with PBS, the serum-labeled 
cells were detected using a HRP-conjugated 
secondary antibody. The labeling was visual-
ized using TMB substrate and detected by 
light microscope.  
 
Lymphocyte proliferation assay 
We used a previously reported MTT as-
say procedure for lymphocyte proliferation 
assay (Babu et al., 2008). Briefly, spleno-
cytes were cultured in 96-well cell culture 
plates (Nunc, Denmark) and the aliquots of 
the antigens were then dispensed into the 
wells, at a final concentration of 10 μg/ml of 
antigen. Wells with splenocytes from mock-
immunized mice were included as negative 
control. As well as ConA-stimulated cell 
suspensions were also included as positive 
control (ConA: Sigma-Aldrich, St. Louis, 
MO, USA). Cultures were incubated at 37 ºC 
in 5 % CO2 humidified incubator for 1-3 
days. The MTT proliferation assay was per-
formed using 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide. After in-
cubation, cells were treated with MTT sol-
vent for 15 minutes at RT. Absorbance was 
measured at OD = 570 nm. 
 
Cytokine assay 
To analyze the phenotype of the specific 
cellular immune response induced by the re-
combinant protein, the supernatant from each 
triplicate well from splenocytes cultures 
were pooled after 72 h and were frozen at -
80 ºC until use. To examine the level of the 
Th1-type cytokine of INF-γ and Th2-type 
cytokine of IL-4, commercially cytokine 
quantitative ELISA kits (mouse INF-γ and 
IL-4 kits, Qiagen, USA) were used according 
to the manufacturer's instructions.  
 
Statistical analysis 
The data were analyzed using one-way 
ANOVA of SPSS software version 22 and 
were expressed as mean ± standard deviation 
(SD) (from certain independent experiments) 
and the P-values of <0.05 were considered 
statistically significant. 
 
RESULTS 
Tetravalent antigen design and expression 
Four consensus ED3 sequences of den-
gue serotypes were fused together by appro-
priate hydrophobic linkers as a tetravalent 
fusion protein (ED3F) (Figure 1A). The 
ED3F protein was predicted to be a 479 ami-
no acid protein with molecular weight of~52 
kDa. In this recombinant protein, the first 
amino acid residue is a vector-encoded me-
thionine followed by 477 amino acid resi-
dues encompassing domain III of all four 
serotypes of dengue envelope protein, the 
linker sequences, and His6-Tag sequence. 
The designed pETD3F construct was trans-
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formed into Origami(DE3) host cells. It has 
been shown that the Origami strain of E. coli 
with glutathione reductase (gor) and thiore-
doxinreductase (trxB) mutations supports the 
formation of disulfide bridges in E. coli 
(Saejung et al., 2006). To identify clones ca-
pable of expressing the desired recombinant 
protein, small-scale cultures of the positive 
clones (selected by PCR) were subjected to 
IPTG induction. A typical induction experi-
ment comparing the polypeptide profile of 
un-induced and induced cultures is shown in 
Figure 1B. It is evident that IPTG induction  
 
A  
 
B  
Figure 1: Amino acid sequence, purification and characterization of the ED3-F antigen. (A) Ami-
no acid sequence of the tetravalent ED3-F antigen. The four ED3 sequences ED3-1, ED3-2, ED3-3 
and ED3-4 were fused together by a repetitive linker sequence (lower case letters). The ED3-F coding 
sequence was cloned into the pET21a plasmid fused to a His6-Tag coding sequence. (B) Lanes 2 and 
3, protein production profiles of bacterial lysates prepared before (lane 2) and after IPTG induction 
(lane 3). Soluble cell extracts were analyzed on a 10 % SDS polyacrylamide gel and stained with 
Coomassie Brilliant Blue. The arrow indicates the 52 kD band representing the ED3-F protein. Lane 5, 
purified ED3-F antigen after the second purification step. Lane 7 and 8, ED3-F tested for immune re-
activity against anti-dengue monoclonal antibodies (lane 6) an anti-His6-Tag antibody (lane 7) by 
Western blot. Lanes 1, 4 and 6 protein molecular weight markers 
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results in the expression of a protein corre-
sponding to the expected molecular weight 
of ~52 kDa. The purified recombinant ED3F 
protein was characterized by Western blot 
analysis. It was shown that the fusion protein 
reacts specifically with pan-dengue specific 
antibody and anti-His-Tag monoclonal anti-
body (Figure 1B). Together, these results 
demonstrated the successful purification and 
characterization of the designed tetravalent 
fusion protein. 
 
Immunogenicity of recombinant proteins 
In order to test the immunogenicity of the 
ED3F protein, a group of mice were immun-
ized subcutaneously with ED3F protein three 
times at two-week intervals. In parallel, 
groups of mice were immunized with four 
monovalent and a tetravalent formulation of 
ED3 proteins (ED3 (1-4) mixture) by using 
the same method (Table 1). The mice in neg-
ative control (G7) were immunized with PBS 
in combination with adjuvant (mock-
immunization). 
Sera from immunized mice were collect-
ed and analyzed for anti-ED3F and anti-
ED3(1-4) antibodies by ELISA. The results 
shown in Figure 2 (A and B) indicate that the 
mice developed high-titer antibody responses 
against the corresponding antigens. To inves-
tigate the profile of expected tetravalent re-
sponse following immunization with ED3F 
protein, reactivity of anti-ED3F serum with 
four ED3 proteins was analyzed separately 
by using indirect ELISA (Figure 2C). As a 
comparison, reactivity of pooled serum from 
G5 with four ED3 proteins was also ana-
lyzed (Figure 2D). Interestingly, these data 
revealed that the potential of tetravalent fu-
sion protein in developing high and balanced 
titer of tetravalent antibody response against 
all four ED3 types. 
Furthermore, the specific reactivity of 
anti-ED3 serum samples with dengue and 
non-dengue flaviviral recombinant ED3 pro-
teins were investigated. According to the re-
sults of dot blotting, all serum samples from 
the immunized mice groups reacted with 
dengue ED3 proteins, there was no signifi-
cant reaction between the antisera and ED3 
proteins of other non-dengue flaviviruses 
(JEV, WNV, and TBEV) (Figure 3A). All 
dengue antigens were reacted with undiluted 
serum samples from the immunized animals. 
The resulted cross-reactivity between the dif-
ferent serotypes can be due to the non-
quantitative nature of the assay. The reactivi-
ty of tetravalent antisera (from G5 and G6) 
with dengue antigens also were investigated 
in cell culture (Figure 3B). All four serotypes 
of dengue virus were recognized by the tet-
ravalent antisera, whereas dengue viruses 
were not detected in mock-infected cell. 
These data prove the dengue vaccine im-
mune sera can recognize the native dengue 
viruses in cell culture. As additional control, 
serum pools and control MAb tested against 
uninfected cells that resulted in no reaction 
response.  
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Figure 2: Antibody titers to ED3 in pooled sera from immunized mice. Sera collected from 
BALB/c mice (n=6) that had been immunized subcutaneously with the recombinant ED3 antigens were 
pooled for each group and the pooled sera were tested at various dilutions for their reactivity to ED3 
antigens by ELISA. The mock-immunized mice serum pool G7 was used as a control. (A) The four 
ED3 proteins ED3-1, ED3-2, ED3-3 and ED3-4 were coated onto ELISA plate as individual antigens or 
as a mixture in order to determine anti-ED3 antibody titers in the pooled sera from monovalent immun-
ized mice. (B) The ED3-F protein was coated onto ELISA plate as antigen to test the anti-ED3-F anti-
body response in pooled sera from ED3(1-4) (G5) and ED3-F (G6) immunized mice. The results 
showed that the mice in both G5 and G6 groups developed antibody responses towards the tetrava-
lent ED3-F antigen.  
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Figure 2 (cont.): Antibody titers to ED3 in pooled sera from immunized mice. (C and D) The re-
activity of the pooled sera from G6 and G5 to monovalent ED3 antigens was investigated, respective-
ly. The monovalent ED3-1, ED3-2, ED3-3, and ED3-4 recombinant antigens were tested by ELISA as 
individual antigens. As a control, a pooled serum from G7 was tested against the ED3(1-4) antigen.  
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Figure 3: Reactivity of immune sera against 
recombinant ED3 and virus infected cells. (A) 
All pooled sera from immunized mice were test-
ed for reactivity against recombinant ED3 anti-
gens from DENV, JEV, WNV and TBEV by an 
immune-dot blotting assay. Recombinant antigen 
was immobilized on nitrocellulose strips, incu-
bated with sera and bound antibodies were de-
tected by a secondary HRP conjugated antibody 
and 4-CN staining. (B) Pooled sera from tetrava-
lent immunizations (G5, G6) were tested for re-
activity against virus antigen. Vero B4 cells were 
infected with DENV and cells were immobilized 
using formaldehyde and permeabilized with 
Tween20. Sera, 1:2 diluted were used as a pri-
mary antibody and a secondary HRP-conjugated 
anti-mouse IgG antibody was used for micro-
scopic detection of the positively stained cells. A 
commercial pan-dengue specific monoclonal an-
tibody diluted 1:10 dilution was used as a refer-
ence (Abnoova, Germany). These data prove the 
dengue vaccine immune sera can recognize the 
native dengue viruses in cell culture. 
 
Cross neutralization of all four dengue 
serotypes 
The major objective of this study was to 
explore whether ED3F can induce cross-
neutralizing antibodies. The neutralizing 
ability of the antiserum from the different 
immunized groups against the four serotypes 
of dengue virus was assessed using FRNT. 
As shown in Table 2, anti-ED3F serum re-
duced the number of FFU when was pre-
incubated with virus. These results indicate 
that tetravalent ED3F protein is able to elicit 
cross-neutralizing antibodies to block all 
four serotypes of dengue virus. While, all of 
the monovalent antiserum samples (sera G1-
G4) showed cross-neutralizing effects, sero-
type specific neutralization was observed on-
ly in high diluted sera (1:80 and 1:40). Inter-
estingly, in a very similar way with anti-
ED3F serum, the serum from immunized 
mice with tetravalent formulation of four 
ED3 proteins (G5) cross-neutralized all four 
serotypes of dengue virus. Complete neutral-
ization of dengue viruses by all anti-ED3 se-
ra was observed up to a dilution of around 
1:40. These data revealed the potential of re-
combinant envelope protein domain III in 
developing neutralizing immune responses 
against dengue virus. However, it should be 
noted that background neutralization was ob-
served by high titers of serum from mock 
immunized group (G7). 
 
Cell proliferation and cytokine profiling  
assays 
According to the MTT assay in three 
days intervals, the splenocytes of the immun-
ized mice showed high proliferation in com-
parison to the negative control (Figure 4). 
Splenocytes in negative control did not show 
comparable proliferation when stimulated 
with tetravalent formulation of ED3 proteins, 
indicating specificity of the proliferation. 
Splenocytes from G5 showed better prolifer-
ation than other groups. Splenocytes from 
unimmunized mice responded to stimulation 
by ConA, nonspecifically (as a positive con-
trol for monitoring of the stimulation level). 
Comparison among duration of treatments 
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Table 2: Virus-neutralization titers of serum pools from immunized mice 
Virus type Serum pools 
G1 G2 G3 G4 G5 G6 G7 
DENV-1 1:80 1:10 1:20 1:20 1:80 1:80 1:2 
DENV-2 1:20 1:80 1:20 1:40 1:80 1:80 1:2 
DENV-3 1:40 1:20 1:80 1:20 1:40 1:80 1:2 
DENV-4 1:10 1:20 1:10 1:80 1:80 1:80 1:2 
The FRNT50 method was used to evaluate neutralization of dengue virus. The neutralizing antibody titers were calculated as the 
maximum serum dilution yielding a 50 % reduction of FFU in comparing with mock-immunized sera (G7). Values are the means 
of duplicate wells and are representative of three independent experiments. 
 
 
Figure 4: Lymphocyte proliferation and cytokine assays. (A) Splenocytes from immunized mice 
(G1-G6) were prepared 2 weeks after the last immunization, and re-stimulated with the corresponding 
antigens for 24, 48, and 72 h. This assay was done using a MTT cell proliferation assay. The spleno-
cytes from mock-immunized group, stimulated by the tetravalent formulation of ED3s, was considered 
as negative control (G7). The splenocytes of the immunized mice showed high level of proliferation in 
comparison with the negative control. Splenocytes from unimmunized mice responded to ConA non-
specifically (C+). There is significance in cell proliferation between different time points (24 h and 72 
h). In comparing with mock immunized group (G7), it can be concluded that the cell proliferations are 
higher in dengue vaccine immunized mice. (B) Cytokine assay upon in vitro re-stimulation of spleno-
cytes. Splenocytes from mice (G1-G6) were re-stimulated by the corresponding antigens, and the lev-
el of two cytokines (INFγ and IL4) was measured using commercial quantitative ELISA kits. The sple-
nocytes from mock-immunized mice were stimulated by the tetravalent ED3 mixture and were consid-
ered as negative control (G7). The splenocytes from non-immunized mice (G8) were stimulated by 
ConA in vitro as a positive control. Data are presented as the mean cytokine concentrations from trip-
licate wells. 
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(24 h and 48 h) did not display negative ef-
fects or significant differences, although the 
overall trend of proliferation was upward. 
Though, there is significance in cell prolifer-
ation between different time points (24 h and 
72 h). In comparing with mock immunized 
group (G7), it can be concluded that the cell 
proliferation is higher in dengue vaccine 
immunized mice. Furthermore, quantitative 
ELISAs were used to detect the secreted 
IFN-γ and IL-4 cytokines from splenocytes 
of the immunized mice re-stimulated with 
the corresponding antigens (Figure 4). Sple-
nocytes of unimmunized mice stimulated by 
ConA were included in cytokine assay as a 
positive control group (G8). In comparison 
with the negative control group (G7), the 
concentration of two measured cytokines in-
creased markedly in all ED3-immunized 
groups. However, in both MTT and cytokine 
assays no significant differences between the 
immunized groups were detected. It is likely 
due to application of high concentration of 
antigens.  
 
DISCUSSION 
Because of an increased risk of develop-
ing DHF and DSS in dengue-infected indi-
viduals with a previous heterologous dengue 
infection (Gubler, 2002), an effective dengue 
vaccine must provide solid and long-lasting 
cross-protection against all four serotypes. 
So, we attempted to develop a tetravalent 
dengue vaccine candidate by using the enve-
lope protein domain III. Recombinant ED3 
proteins show immunogenic and protective 
properties in animals (Crill and Roehrig, 
2001, Yang et al., 2012, Coconi-Linares et 
al., 2013, Block et al., 2010). Although ED3-
based vaccine represents only a fraction of 
the envelope protein, the removal of other 
epitopes that elicit non-neutralizing cross-
reactive antibodies, may reduce the risk of 
disease progression to DHF and DSS 
(Bernardo et al., 2009). The immunogenicity 
of ED3 fragment of type 3 dengue virus was 
reported previously (Fahimi et al., 2014). 
However, this study was aimed to design a 
tetravalent vaccine candidate in the form of a 
physical mixture of four ED3 fragments or in 
a single chimeric protein. One approach that 
has been suggested to minimize the possibil-
ity of antibody-dependent enhancement of 
infection, occurring after vaccination, is to 
design a tetravalent subunit vaccine contain-
ing potent neutralizing epitopes against all 
four serotypes. In the current study, a tetra-
valent ED3-based recombinant antigen 
(ED3F) was designed and expressed. To fa-
cilitate easy purification, ED3F protein and 
four ED3 proteins with a C-terminal 6x-
HisTag were expressed in soluble form and 
without any bulky fusion partner like MBP 
or GST. Immunogenicity of this tetravalent 
fusion protein was verified and also com-
pared with tetravalent formulation of ED3s. 
The reactivity of anti-ED3F antiserum 
against ED3 proteins demonstrated that this 
new tetravalent immunogen elicited antibody 
responses against all four ED3 types. The 
specific reactivity of anti-ED3 sera with re-
combinant dengue ED3 proteins was shown 
in a dot blotting assay, in comparing with 
ED3 proteins of the other flaviviruses. Fur-
thermore, the tetravalent anti-ED3 serum 
samples were able to recognize all dengue 
serotypes in cell culture. On the other hand, 
the results of neutralization assays revealed 
that the elicited tetravalent immune response 
was capable to neutralize all four serotypes 
of dengue virus. These results indicated that 
the (EAAAK)4 linkers were effective in 
equal expression and supportive for accessi-
bility of epitopes in ED3F structure. It was 
reported that a tetravalent dengue vaccine 
candidate with (Gly4Ser)3 linkers between 
ED3 fragments, results in induction of an 
unbalanced immune response in mice (Chen 
et al., 2007). The authors discussed that 
some antigenic determinants may be buried 
in the protein interior. Hence, a more suita-
ble linker was used in a way to balance four 
consensus ED3 proteins and expose antigen-
ic determinants. In addition, cell-mediated 
immunity was evaluated by antigen-
stimulated splenocyte proliferation assay and 
cytokine production in vitro. Splenocyte 
from all immunized mice showed significant 
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levels of proliferation in response to in vitro 
re-stimulation with ED3 antigens. The re-
sults of cytokine assays showed significant 
rise in the levels of IFN-γ and IL-4. IgG2a 
and IgG3 responses are enhanced by IFN-γ, 
and B cells are capable of secreting IgG1 in 
the presence of IL-4 (Stevens et al., 1988; Le 
Gros et al., 1990). IFN-γ has been described 
as a mediator of the cellular immune re-
sponse and plays a distinctive role in antivi-
ral activity against dengue viruses (Shresta et 
al., 2004; Dejnirattisai et al., 2008). Fur-
thermore, it has been shown that IFN-γ is as-
sociated with protection against dengue fever 
and/or viremia in human (Gunther et al., 
2011). Based on these data and the presence 
of IFN-γ as a marker of the Th1 response and 
IL-4 as a marker of the Th2 response, it may 
be suggested that both of the Th1- and Th2-
type immune responses were induced fol-
lowing vaccination of mice. Although, the 
results of this study were not revealed signif-
icant differences between the application of a 
mixture of four monovalent antigens and a 
tetravalent antigen, but a single tetravalent 
antigen shows basic advantages over physi-
cally mixture of four monovalent antigens 
such as ease of production and formulation. 
In conclusion the tetravalent ED3F fu-
sion protein was able to enhance cross-
neutralizing antibody responses against all 
four serotypes of dengue virus. The new 
ED3F antigen can be used to develop a tetra-
valent subunit vaccine candidate for preven-
tion of dengue infections.  
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